Dr Lipson continues his discussion as he highlights significant results from the NADINA trial. Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of ...
Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial. The trial results suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback